 |
 |
 |
 |
 |
 |
 |
 |
-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Protease Inhibitors in Development
- A Clinical Overview of Brecanavir (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Brecanavir Shows Good Cross-Resistance Profile (August 17, 2006)
In XVI International AIDS Conference - Brecanavir Shows Favorable Pharmacokinetics When Combined With Select PIs in Double-Boosted Regimens (August 15, 2006)
In XVI International AIDS Conference - New Protease Inhibitor Brecanavir Shown to Be Safe and Effective in Small Study (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Safety and Pharmacokinetic Data for 640385, a New Protease Inhibitor in Development (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Drug Development News: Gilead (May/June 2004)
A new prodrug technology targeting lymphocytes could all but revolutionize protease inhibitor therapy.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Gilead Aims to Begin Evaluation of New Protease Inhibitor (January 13, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Out of the Lab: A New Target and a New Agent From Gilead (December 2003)
A study examines the anti-HIV properties of a betulinic acid derivative, and Gilead hopes to begin human studies of a new protease inhibitor.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Protease Inhibitors in Development
An overview from Edwin DeJesus, M.D.
From The Body PRO
  |
  |